After finding that Nexvax2 did not provide, "meaningful protection from gluten exposure when compared with placebo," ImmusanT pulled the plug on their trial. Mike and Cam share their thoughts and also discuss a highly informative article written by Kelly Carter, a participant in the study. In the end, we are optimistic that more good will come out of this down the line, and we talk about why trials like these are so important to help us hopefully find a cure for celiac disease.
